دورية أكاديمية
Interleukin (IL)-21 and IL-21 receptor expression in peripheral T and B cells of patients with breast cancer.
العنوان: | Interleukin (IL)-21 and IL-21 receptor expression in peripheral T and B cells of patients with breast cancer. |
---|---|
المؤلفون: | Babaeinia E; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. e.babaeinia.77@gmail.com., Ghods A; Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. atrighods@yahoo.com., Rasolmali R; Department of Pathology, Shiraz Central Hospital, Shiraz, Iran. rasolmalir@yahoo.com., Talei AR; Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. taleiar@gmail.com., Mehdipour F; Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. mehdipourf@sums.ac.ir., Ghaderi A; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ghaderia@sums.ac.ir. |
المصدر: | Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 2024 Apr 28; Vol. 70 (4), pp. 15-22. Date of Electronic Publication: 2024 Apr 28. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: C.M.B. Association Country of Publication: France NLM ID: 9216789 Publication Model: Electronic Cited Medium: Internet ISSN: 1165-158X (Electronic) Linking ISSN: 01455680 NLM ISO Abbreviation: Cell Mol Biol (Noisy-le-grand) Subsets: MEDLINE |
أسماء مطبوعة: | Publication: <2001->: Noisy-Le-Grand, France : C.M.B. Association Original Publication: Noisy-le-Grand, France : R. Wegmann, 1992- |
مواضيع طبية MeSH: | Interleukins*/metabolism , Interleukins*/blood , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/immunology , CD4-Positive T-Lymphocytes*/metabolism , CD4-Positive T-Lymphocytes*/immunology , Receptors, Interleukin-21*/metabolism , Receptors, Interleukin-21*/genetics , B-Lymphocytes*/metabolism , B-Lymphocytes*/immunology, Humans ; Female ; Middle Aged ; Adult ; Case-Control Studies ; Aged ; Flow Cytometry |
مستخلص: | IL-21 is a cytokine with versatile antitumor and pro-tumorigenic activities. It is mainly produced by CD4+ T cells and B cells are one of its pivotal targets. In this study, we assessed and compared the expression of IL-21 by CD4+ T cells and the IL-21 receptor (IL-21R) on B cells in the peripheral blood of women with breast cancer and healthy individuals. Blood samples were taken from both patients and controls. Mononuclear cells were seperated using Ficoll-Hypaque density gradient centrifugation. These isolated cells were then stained with either anti-CD19/anti-IL-21R or anti-CD4/anti-IL-21 antibodies and analyzed using flow cytometry. The results showed that there was no significant difference in the percentage of IL-21R+ B cells and IL-21+CD4+ T cells between patients and controls. However, the percentage of CD4+ T cells decreased significantly in patients with breast cancer (P=0.003). This decline was observed from the early stage and before lymph node (LN) involvement. In comparison to the control group, IL-21R+ B cells were relatively lower in patients with stages I+II and those with fewer than 4 involved LNs. The intensity of IL-21 expression in T cells was associated with HER2 expression (P=0.029). Furthermore, we found that the majority of IL-21R+ B cells exhibited a naïve phenotype and most of IL-21+CD4+ T cells did not produce IFN-γ or IL-17. In conclusion, breast cancer from the early stages leads to a significant reduction in the proportion of peripheral CD4+ T cells. However, we did not find a significant change in IL-21 and its receptor expression during disease progression. |
المشرفين على المادة: | 0 (Interleukins) MKM3CA6LT1 (interleukin-21) 0 (Receptors, Interleukin-21) |
تواريخ الأحداث: | Date Created: 20240428 Date Completed: 20240428 Latest Revision: 20240522 |
رمز التحديث: | 20240522 |
DOI: | 10.14715/cmb/2024.70.4.3 |
PMID: | 38678632 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1165-158X |
---|---|
DOI: | 10.14715/cmb/2024.70.4.3 |